Mind Medicine (MindMed) (MNMD) Stock Overview
A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MNMD Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.16 |
| 52 Week High | US$14.30 |
| 52 Week Low | US$4.70 |
| Beta | 3.31 |
| 1 Month Change | 45.58% |
| 3 Month Change | 32.80% |
| 1 Year Change | 108.56% |
| 3 Year Change | 368.33% |
| 5 Year Change | 0.84% |
| Change since IPO | 51.11% |
Recent News & Updates
Recent updates
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Oct 14Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Apr 21MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Jan 29Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Nov 04Psychedelic Stocks: Focus On Their Cash
Aug 15MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Jun 05Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20Shareholder Returns
| MNMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.3% | 0.7% | 1.2% |
| 1Y | 108.6% | -5.7% | 16.3% |
Return vs Industry: MNMD exceeded the US Pharmaceuticals industry which returned -6.1% over the past year.
Return vs Market: MNMD exceeded the US Market which returned 14.7% over the past year.
Price Volatility
| MNMD volatility | |
|---|---|
| MNMD Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MNMD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 74 | Rob Barrow | www.mindmed.co |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MNMD fundamental statistics | |
|---|---|
| Market cap | US$1.00b |
| Earnings (TTM) | -US$114.52m |
| Revenue (TTM) | n/a |
Is MNMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$114.52m |
| Earnings | -US$114.52m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 22.2% |
How did MNMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 14:35 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mind Medicine (MindMed) Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |